





Contractor Details	Type/ size of legal entity	Place of performance of contract activities	Logo
<p><u>Main contractor</u></p> <p>FUNDACIO CENTRE DE REGULACIO GENOMICA PRBB Building, Dr Aiguader 88 08003 Barcelona, SPAIN MONICA BAYES monica.bayes@cnag.crg.eu</p>	Research institute	<p>% of contract value allocated to main contractor: 94.67 %</p> <p>% of activities for the contract performed by the main contractor in EU Member States or countries associated with Horizon 2020: 100 %</p>	
<p><u>Subcontractors (if applicable)</u></p> <p>1. TECNO-MED INGENIEROS, S.L. Marie Curie 8, 08042, Barcelona, SPAIN XAVIER CANALS RIERA Phone nr contact person xcanals@tecno-med.es</p>	SME	<p>% of contract value allocated to subcontractor [1]: 2.28%</p> <p>% of activities for the contract performed by subcontractor [1] in EU Member States or countries associated with Horizon 2020: 100 %</p>	
<p>2. GENESIS Biomed SL . Parc Científic de Barcelona, Baldri Reixac 4-8, 08028 Barcelona, SPAIN Josep Lluís Falcó josep.lluis.falco@genesis-biomed.com</p>	SME	<p>% of contract value allocated to subcontractor [2]: 1.88 %</p> <p>% of activities for the contract performed by subcontractor [2] in EU Member States or countries associated with Horizon 2020: 100 %</p>	
<p>3. Internet Security Auditors, S.L. Santander 101 (Edificio A. 2º), 08030 Barcelona, SPAIN Antoni Nicolás anicolas@isecauditors.com</p>	SME	<p>% of contract value allocated to subcontractor [3]: 1.17 %</p> <p>% of activities for the contract performed by subcontractor [3] in EU Member States or countries associated with Horizon 2020: 100 %</p>	

### Project abstract

The Cancer Analysis GPAP will enable streamlined and user-friendly management and analysis of Next Generation Sequencing data in adult and paediatric cancers, common and rare. It will be structured around a well-defined and streamlined workflow, envisioning different types of users, each with specific roles and permissions. A set of pre-defined but still customisable pipelines, will allow to analyse sequencing data input automatically according to the clinical request and the experimental information. Quality control metrics and messages will be provided at different stages of the process. The platform will have a modular design built upon Singularity containers, enabling

installation in High Performance Computing clusters and Cloud Computing Services. The modular approach will provide flexibility while facilitating updates and backups. Security will be incorporated in all the stages of the Software Development Life Cycle to take into account the EU GDPR and relevant ISO and IVDR requirements.

### **Previous EU funding**

Is the project based on / a continuation of R&D activities that were previously funded by the EU?: YES

If yes, identify this EU funding:

FP7-HEALTH-2012-INNOVATION-1, RD-CONNECT: An integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research, GA 305444

H2020-SC1-2016-2017, Solving the unsolved Rare Diseases, GA 779257

H2020-SC1-BHC-2018-2020, European Joint Programme on Rare Diseases, GA 825575

